Reliability of antiarrhythmic drug plasma concentration monitoring.

abstract：:Interleukins and tumour necrosis factor (TNF) are a complex group of proteins and glycoproteins able to exert pleiotropic effects with respect to a number of different target cells. In physiological conditions, they are induced and released in basal amounts only in restricted microenvironments where they have paracrin...

journal_title：Clinical pharmacokinetics

authors： Bocci V

更新日期：1991-10-01 00:00:00

abstract：:The US Food and Drug Administration (FDA) draft guidance for industry on drug interaction studies recommends, but does not mandate, that both cigarette smokers and non-smokers can be used to study drug metabolism in clinical trials, and that important results related to smoking should be included in drug labelling to ...

journal_title：Clinical pharmacokinetics

authors： Li H,Shi Q

更新日期：2015-05-01 00:00:00

abstract：BACKGROUND AND AIMS:In this study, we evaluate the performance of allometric concepts to predict the implications of age and size on the pharmacokinetics of lamotrigine, and assess the dose rationale across different age groups from 0.2 to 91 years. METHODS:An allometrically scaled pharmacokinetic model was developed ...

journal_title：Clinical pharmacokinetics

authors： van Dijkman SC,de Jager NCB,Rauwé WM,Danhof M,Della Pasqua O

更新日期：2018-08-01 00:00:00

abstract：BACKGROUND:Mycophenolate mofetil is the prodrug of mycophenolic acid (MPA) and is used as an immunosuppressant following renal, heart, lung and liver transplantation. Although MPA plasma concentrations have been shown to correlate with clinical outcome, there is considerable inter- and intrapatient pharmacokinetic vari...

journal_title：Clinical pharmacokinetics

authors： van Hest RM,van Gelder T,Vulto AG,Mathot RA

更新日期：2005-01-01 00:00:00

abstract：:The critically ill patient occupies an increasing amount of time and bed space in modern hospital practice, and also commands increasing expenditure. Drug therapy in these patients has, in the past, been based on data derived from healthy volunteers, fit anaesthetised patients undergoing minor operative procedures, or...

journal_title：Clinical pharmacokinetics

authors： Bodenham A,Shelly MP,Park GR

更新日期：1988-06-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated clinical activity in a number of different cancer types. The objectives of this study were to characterize the pharmacokinetics of abemaciclib in cancer patients using population pharmacokinetic (popPK) modelin...

journal_title：Clinical pharmacokinetics

authors： Tate SC,Sykes AK,Kulanthaivel P,Chan EM,Turner PK,Cronier DM

更新日期：2018-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Labetalol is frequently prescribed for the treatment of hypertension during pregnancy; however, the influence of pregnancy on labetalol pharmacokinetics is uncertain, with inconsistent findings reported by previous studies. This study examined the population pharmacokinetics of oral labetalol ...

journal_title：Clinical pharmacokinetics

authors： Fischer JH,Sarto GE,Hardman J,Endres L,Jenkins TM,Kilpatrick SJ,Jeong H,Geller S,Deyo K,Fischer PA,Rodvold KA

更新日期：2014-04-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Vicriviroc is a small-molecule CCR5 antagonist currently in development for the treatment of HIV in patients on a regimen containing a ritonavir-boosted protease inhibitor. As renal disease and renal dysfunction are prevalent in the HIV-infected population, patients with varying degrees of rena...

journal_title：Clinical pharmacokinetics

authors： Kasserra C,Sansone-Parsons A,Keung A,Tetteh E,Assaf M,O'Mara E,Marbury T

更新日期：2010-06-01 00:00:00

abstract：:Acute coronary syndromes (ACS) remain life-threatening disorders associated with high morbidity and mortality, despite advances in treatment over the last decade. Adenosine diphosphate-induced platelet activation via P2Y(12) receptors plays a pivotal role in the pathophysiology of ACS. The current standard of treatmen...

journal_title：Clinical pharmacokinetics

authors： Teng R

更新日期：2012-05-01 00:00:00

abstract：:All of the commonly used anticonvulsants drugs, except possibly primidone, are cleared from the human body mainly by metabolism. The metabolites of phenytoin, phenobarbital and ethosuximide have so far not been shown to possess significant pharmacological activity. However, carbamazepine-10,11-epoxide, derived from ca...

journal_title：Clinical pharmacokinetics

authors： Eadie MJ

更新日期：1991-07-01 00:00:00

abstract：:Physiologically-based pharmacokinetic (PBPK) modeling is a powerful tool used to characterize maturational changes in drug disposition to inform dosing across childhood; however, its use is limited in pediatric drug development. Access to pediatric pharmacokinetic data is a barrier to widespread application of this mo...

journal_title：Clinical pharmacokinetics

authors： Hornik CP,Wu H,Edginton AN,Watt K,Cohen-Wolkowiez M,Gonzalez D

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting formulation of insulin aspart (IAsp). This post hoc analysis investigated the pharmacokinetics of faster aspart versus IAsp, measured as free or total IAsp, and the relationship between anti-IAsp antibodies and the pharmacokinetics/pharmacody...

journal_title：Clinical pharmacokinetics

authors： Haahr H,Pieber TR,Mathieu C,Gondolf T,Shiramoto M,Erichsen L,Heise T

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:Recombinant methionyl human leptin (r-metHuLeptin) has demonstrated efficacy in improving hormonal and metabolic parameters in leptin-deficient states, and it has been suggested that leptin replacement may reverse metabolic adaptations during weight loss interventions. The pharmacokinetics of subcutaneously ...

journal_title：Clinical pharmacokinetics

authors： Chan JL,Wong SL,Mantzoros CS

更新日期：2008-01-01 00:00:00

abstract：:The present article should be read in conjunction with the original review published in the Journal in 1983. There is no new information of major significance about the pharmacokinetics of levonorgestrel, norethisterone (norethindrone) or ethinylestradiol, although it has been shown that the concentrations of these ho...

journal_title：Clinical pharmacokinetics

authors： Shenfield GM,Griffin JM

更新日期：1991-01-01 00:00:00

abstract：:The relation between steady-state plasma ethosuximide level and drug dose was studied in 46 patients. In this population, plasma drug levels were proportional to drug dose, expressed on a body weight basis. Age did not alter this relationship, but plasma levels increased more rapidly, relative to dose, in females than...

journal_title：Clinical pharmacokinetics

authors： Smith GA,McKauge L,Dubetz D,Tyrer JH,Eadie MJ

更新日期：1979-01-01 00:00:00

abstract：BACKGROUND:Tildrakizumab is an anti-interleukin-23p19 monoclonal antibody recently approved for the treatment of chronic plaque psoriasis. METHODS:This analysis characterizes the population pharmacokinetics of subcutaneous tildrakizumab and identifies covariates influencing exposure in 2098 healthy volunteers and subj...

journal_title：Clinical pharmacokinetics

authors： Jauslin P,Kulkarni P,Li H,Vatakuti S,Hussain A,Wenning L,Kerbusch T

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND:For imatinib, a relationship between systemic exposure and clinical outcome has been suggested. Importantly, imatinib concentrations are not stable and decrease over time, for which several mechanisms have been suggested. In this study, we investigated if a decrease in alpha-1 acid glycoprotein (AGP) is the ...

journal_title：Clinical pharmacokinetics

authors： Bins S,Eechoute K,Kloth JS,de Man FM,Oosten AW,de Bruijn P,Sleijfer S,Mathijssen RH

更新日期：2017-03-01 00:00:00

abstract：:Peak expiratory flow rate, adverse effects and serum theophylline concentration were measured during treatment of episodes of severe airways obstruction. 174 patients were randomised to target theophylline concentrations of 10 mg/L or 20 mg/L. The recovery of peak flow rate towards normal values was explicable in term...

journal_title：Clinical pharmacokinetics

authors： Holford N,Hashimoto Y,Sheiner LB

更新日期：1993-12-01 00:00:00

abstract：BACKGROUND:Bitopertin (RG1678) is a glycine reuptake inhibitor currently in phase 3 trials for treatment of schizophrenia. This paper describes the use of physiologically based pharmacokinetic (PBPK) modelling and preclinical data to gain insights into and predict bitopertin clinical pharmacokinetics. METHODS:Simulati...

journal_title：Clinical pharmacokinetics

authors： Parrott N,Hainzl D,Alberati D,Hofmann C,Robson R,Boutouyrie B,Martin-Facklam M

更新日期：2013-08-01 00:00:00

abstract：:High dosage busulfan (1 mg/kg orally every 6 hours x 16 doses) is frequently used in preparative regimens for haemopoietic stem cell transplantation (HSCT). Busulfan is well absorbed after oral administration, exhibits low protein binding and is metabolised through conjugation with glutathione to form a thiophenium io...

journal_title：Clinical pharmacokinetics

authors： McCune JS,Gibbs JP,Slattery JT

更新日期：2000-08-01 00:00:00

abstract：:Leflunomide is the first disease-modifying antirheumatic drug to be approved for rheumatoid arthritis in the past 10 years. Orally administered leflunomide is almost completely converted into its active metabolite A77 1726 (hereafter referred to as M1). M1 displays linear pharmacokinetics at the dosages of leflunomide...

journal_title：Clinical pharmacokinetics

authors： Rozman B

更新日期：2002-01-01 00:00:00

abstract：:Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α4β7-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely active ulcerative colitis (...

journal_title：Clinical pharmacokinetics

authors： Rosario M,Dirks NL,Milch C,Parikh A,Bargfrede M,Wyant T,Fedyk E,Fox I

更新日期：2017-11-01 00:00:00

abstract：:Alemtuzumab is a humanized monoclonal antibody against CD52 and causes depletion of T and B lymphocytes, monocytes, and NK cells. Alemtuzumab is registered for the treatment of multiple sclerosis (MS) and is also used in chronic lymphocytic leukemia (CLL). Alemtuzumab is used off-label in kidney transplantation as ind...

journal_title：Clinical pharmacokinetics

authors： van der Zwan M,Baan CC,van Gelder T,Hesselink DA

更新日期：2018-02-01 00:00:00

abstract：:Antipsychotics may cause serious adverse cardiovascular effects, including prolonged QT interval and sudden death. This review considers antipsychotic-induced cardiovascular events from three perspectives: high-risk drugs, high-risk individuals and high-risk drug interactions. Pharmacokinetic drug interactions involvi...

journal_title：Clinical pharmacokinetics

authors： Brown CS,Farmer RG,Soberman JE,Eichner SF

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase currently being developed for the management of hyperuricemia in patients with gout. OBJECTIVE:To investigate the pharmacokinetics, pharmacodynamics and safety of febuxostat over a range of oral doses in healthy subjects. METHODS:In a...

journal_title：Clinical pharmacokinetics

authors： Khosravan R,Grabowski BA,Wu JT,Joseph-Ridge N,Vernillet L

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Buprenorphine has been shown to be effective in treating infants with neonatal opioid withdrawal syndrome. However, an evidence-based buprenorphine dosing strategy has not been established in the treatment of neonatal opioid withdrawal syndrome because of a lack of exposure-response data. The a...

journal_title：Clinical pharmacokinetics

authors： Mizuno T,McPhail BT,Kamatkar S,Wexelblatt S,Ward L,Christians U,Akinbi HT,Vinks AA

更新日期：2020-09-17 00:00:00

abstract：BACKGROUND AND OBJECTIVE:A simple approach is proposed to predict drug clearance in children when no paediatric data are available for drugs metabolised by cytochromes. METHODS:The maturation functions of cytochrome activity and binding proteins in plasma were combined with several measures of body size to describe dr...

journal_title：Clinical pharmacokinetics

authors： Cerruti L,Bleyzac N,Tod M

更新日期：2018-07-01 00:00:00

abstract：OBJECTIVE:To evaluate the dose proportionality and linearity and pharmacokinetic profile of desloratadine after single oral doses over the range of 5 to 20mg. DESIGN:Single centre, randomised, open-label, 4-way crossover study in which healthy adults received single doses of desloratadine (5, 7.5, 10 and 20mg) in 4 di...

journal_title：Clinical pharmacokinetics

authors： Gupta S,Banfield C,Affrime M,Marco A,Cayen M,Herron J,Padhi D

更新日期：2002-01-01 00:00:00

abstract：:Pregnancy is a specific dynamic state, and the potential usefulness of caring for a disorder in the fetus or the mother is now well established. Previously, pregnant women have been excluded from clinical trials, therefore only a few studies concerning evaluation of the pregestational metabolism or transplacental tran...

journal_title：Clinical pharmacokinetics

authors： Bourget P,Roulot C,Fernandez H

更新日期：1995-02-01 00:00:00

abstract：OBJECTIVE:To evaluate the effect of cilostazol administration on warfarin pharmacokinetics and pharmacodynamics following a single 25 mg dose of warfarin. DESIGN:A randomised double-blind 2-period crossover with healthy volunteers receiving either 100 mg cilostazol twice daily for 13 days or matching placebo twice dai...

journal_title：Clinical pharmacokinetics

authors： Mallikaarjun S,Bramer SL

更新日期：1999-01-01 00:00:00